MBRX
Moleculin Biotech Inc
NASDAQ: MBRX · HEALTHCARE · BIOTECHNOLOGY
$2.34
-4.38% today
Updated 2026-06-05
Market cap
$14.09M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-16.16
Dividend yield
—
52W range
$2 – $24
Volume
0.2M
WallStSmart proprietary scores
26
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C5.0
Quality
C+3.0
Profitability
D5.0
Valuation
C+2/9
Piotroski F-Score
Weak
-15.4
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →199 stocks currently score above 75
Price targets
Analyst target
$21.00
+797.44%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
1 Strong Buy2 Buy0 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Debt/equity 0.01x — low leverage
Risks
- Piotroski 2/9 — weak financial health
- Altman Z -15.36 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-6.11M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $-29.02M | $-29.77M | $-21.76M | $-33.56M | $-12.85M |
| EPS | — | — | — | — | $-16.16 |
| Free cash flow | $-27.71M | $-24.23M | $-23.88M | $-22.73M | $-6.11M |
| Profit margin | — | — | — | — | — |
Peer comparison
Smart narrative
Moleculin Biotech Inc trades at $2.34. Our Smart Value Score of 26/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of -15.36, it sits in the distress.
Frequently asked questions
What is Moleculin Biotech Inc's stock price?
Moleculin Biotech Inc (MBRX) trades at $2.34.
Is Moleculin Biotech Inc overvalued?
Moleculin Biotech Inc carries a Smart Value Score of 26/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Moleculin Biotech Inc (MBRX)?
The 12-month analyst consensus target is $21.00, about 797.4% above the current $2.34. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
Altman Z-Score?
Moleculin Biotech Inc's Altman Z-Score is -15.36, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio—
ROE-199.78%
Beta1.77
50D MA$2.47
200D MA$5.87
Shares out0.01B
Float0.01B
Short ratio—
Avg volume0.2M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—